OncoMatch/Clinical Trials/NCT06527495
Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
Is NCT06527495 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Sorafenib for hcc.
Treatment: Sorafenib — The current study will aim to maximize the therapeutic effect and to minimize the adverse effects of sorafenib in HCC through pharmacogenomic analysis of VEGFA and KDR genetic polymorphisms.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Demographics
Prior therapy
Cannot have received: tyrosine kinase inhibitor
Patients not treated with systemic TKIs
Lab requirements
Liver function
Child-Pugh grade C for liver function [excluded]
Patients with Child-Pugh grade C for liver function. Patients with severe organ dysfunction such as heart, lung, and kidney. Patients with severe coagulation dysfunction were uncorrectable.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06527495 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior tyrosine kinase inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages